---
title: "Shareholders of Novoprotein, Heze Qiaobei and Shanghai Pujin, plan to reduce their holdings by no more than 0.61% of the shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247667035.md"
description: "According to the Zhitong Finance APP, Novoprotein announced that its shareholders Heze Qiaobei and Shanghai Pujin plan to reduce their holdings in the company through centralized bidding and block trading due to their own operational development and funding needs. Among them, Heze Qiaobei plans to reduce its holdings by no more than 162,000 shares (with a planned reduction ratio of no more than 0.2308%), while Shanghai Pujin plans to reduce its holdings by no more than 263,200 shares (with a planned reduction ratio of no more than 0.3750%)"
datetime: "2025-07-08T13:52:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247667035.md)
  - [en](https://longbridge.com/en/news/247667035.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247667035.md)
generator: "portal-rs"
---

# Shareholders of Novoprotein, Heze Qiaobei and Shanghai Pujin, plan to reduce their holdings by no more than 0.61% of the shares

According to the Zhitong Finance APP, Novoprotein (688137.SH) announced that its shareholders Heze Qiaobei and Shanghai Pujin plan to reduce their holdings of the company's shares through centralized bidding and block trading due to their own operational development and funding needs. Among them, Heze Qiaobei plans to reduce its holdings by no more than 162,000 shares (with a planned reduction ratio of no more than 0.2308%), while Shanghai Pujin plans to reduce its holdings by no more than 263,200 shares (with a planned reduction ratio of no more than 0.3750%)

### Related Stocks

- [688137.CN](https://longbridge.com/en/quote/688137.CN.md)

## Related News & Research

- [Gold Rallies to 3-Month High](https://longbridge.com/en/news/296629959.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)
- [Silver Pony Announces OTC Symbol Change to PONIF Following Name Change | CCCFD Stock News](https://longbridge.com/en/news/296454882.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**